Future Aspects

PNS research has progressed considerably during the past 20 years. The classification of separate disease entities and the improved diagnostic possibilities offered by antibody detection have contributed much to the increased clinical awareness of PNS. Progress made in the research of these diseases has not only elucidated the underlying mechanisms but has also brought new insight into tumor immunology in general. Nevertheless, many questions remain unanswered. The pathogenesis of the PNS and the effects of the immune reponses on a growing tumor are still uncertain. The PNS represents a therapeutic challenge, and new treatment strategies need to be designed. New antibody targets will be identified in the future, and the presence of ion channel antibodies in both paraneoplastic and nonparaneoplastic disease is of great interest. Finally, an unresolved issue is why so few patients develop PNS, although tumors frequently express onconeural antigens. Hopefully, future research can expand knowledge of the probable dysregulation of the immune system in these individuals and yield insight that can be applied not only to PNS but also to other autoimmune diseases.

References

  • 1] Posner JB. Paraneoplastic syndromes. Curr Opin Neurol 1997; 10(6):471-476.
  • 2] Rees J. Paraneoplastic syndromes. Curr Opin Neurol 1998; 11(6):633-637.
  • 3] Bataller L, Dalmau J. Paraneoplastic neurologic syndromes. Neurol Clin 2003; 21(1): 221-247. ix.
  • 4] van Oosterhout AG, van de Pol M, ten Velde GP, Twijnstra A. Neurologic disorders in 203 consecutive patients with small cell lung cancer. Results of a longitudinal study. Cancer 1996; 77(8):1434-1441.
  • 5] Darnell RB, Posner JB. Observing the invisible: Successful tumor immunity in humans. Nat Immunol 2003; 4(3):201.
  • 6] Posner JB. Paraneoplastic syndromes. Neurol Clin 1991; 9(4):919-936.
  • 7] Roberts WK, Darnell RB. Neuroimmunology of the paraneoplastic neurological degenerations. Curr Opin Immunol 2004; 16(5):616-622.
  • 8] Rauer S, Andreou I. Tumor progression and serum anti-HuD antibody concentration in patients with paraneoplastic neurological syndromes. Eur Neurol 2002; 47(4):189-195.
  • 9] Graus F, Dalmou J, Rene R, Tora M, Malats N, Verschuuren JJ, et al. Anti-Hu antibodies in patients with small-cell lung cancer: Association with complete response to therapy and improved survival. J Clin Oncol 1997; 15(8):2866-2872.
  • 10] Keime-Guibert F, Graus F, Broet P, Rene R, Molinuevo JL, Ascaso C, et al. Clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumor. Neurology 1999; 53(8):1719-1723.
  • 11] Darnell RB, DeAngelis LM. Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet 1993; 341(8836):21-22.
  • 12] Voltz R. Paraneoplastic neurological syndromes: An update on diagnosis, pathogenesis, and therapy. Lancet Neurol 2002; 1(5):294-305.
  • 13] Turk MJ, Wolchok JD, Guevara-Patino JA, Goldberg SM, Houghton AN. Multiple pathways to tumor immunity and concomitant autoimmunity. Immunol Rev 2002; 188:122-135.
  • 14] Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neuro-surg Psychiatry 2004; 75(8):1135-1140.
  • 15] Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autoantibody type 2: Paraneoplastic accompaniments. Ann Neurol 2003; 53(5):580-587.
  • 16] Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol 2004; 56(5):715-719.
  • 17] Anderson NE, Cunningham JM, Posner JB. Autoimmune pathogenesis of paraneoplastic neurological syndromes. Crit Rev Neurobiol 1987; 3(3):245-299.
  • 18] Anderson NE, Posner JB. Antineuronal autoantibodies in neurologic paraneoplastic syndromes. Ann NY Acad Sci 1988; 540:440-441.
  • 19] Musunuru K, Darnell RB. Paraneoplastic neurologic disease antigens: RNA-binding proteins and signaling proteins in neuronal degeneration. Annu Rev Neurosci 2001; 24:239-262.
  • 20] Yang YY, Yin GL, Darnell RB. The neuronal RNA-binding protein Nova-2 is implicated as the autoantigen targeted in POMA patients with dementia. Proc Natl Acad Sci USA 1998; 95(22):13254-13259.
  • 21] Musunuru K. Cell-specific RNA-binding proteins in human disease. Trends Cardiovasc Med 2003; 13(5):188-195.
  • 22] Manley GT, Smitt PS, Dalmau J, Posner JB. Hu antigens: Reactivity with Hu antibodies, tumor expression, and major immunogenic sites. Ann Neurol 1995; 38(1):102-110.
  • 23] Rosenfeld MR, Eichen JG, Wade DF, Posner JB, Dalmau J. Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol 2001; 50(3):339-348.
  • 24] Dalmau J, Gultekin SH, Voltz R, Hoard R, DesChamps T, Balmaceda C, et al. Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. Brain 1999; 122(Pt. 1):27-39.
  • 25] Corradi JP, Yang C, Darnell JC, Dalmau J, Darnell RB. A post-transcriptional regulatory mechanism restricts expression of the paraneoplastic cerebellar degeneration antigen cdr2 to immune privileged tissues. J Neurosci 1997; 17(4):1406-1415.
  • 26] Matsubara S, Yamaji Y, Sato M, Fujita J, Takahara J. Expression of a photoreceptor protein, recoverin, as a cancer-associated retinopathy autoantigen in human lung cancer cell lines. Br J Cancer 1996; 74(9):1419-1422.
  • 27] Subramanian L, Polans AS. Cancer-related diseases of the eye: The role of calcium and calcium-binding proteins. Biochem Biophys Res Commun 2004; 322(4):1153-1165.
  • 28] Charrier E, Reibel S, Rogemond V, Aguera M, Thomasset N, Honnorat J. Collapsin response mediator proteins (CRMPs): Involvement in nervous system development and adult neurodegenerative disorders. Mol Neurobiol 2003; 28(1):51-64.
  • 29] Pittock SJ, Lucchinetti CF, Parisi JE, Benarroch EE, Mokri B, Stephan CL, et al. Amphiphysin autoimmunity: Paraneoplastic accompaniments. Ann Neurol 2005; 58(1): 96-107.
  • 30] Yu Z, Kryzer TJ, Griesmann GE, Kim K, Benarroch EE, Lennon VA. CRMP-5 neuronal autoantibody: Marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001; 49(2):146-154.
  • 31] Mason WP, Graus F, Lang B, Honnorat J, Delattre JY, Valldeoriola F, et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain 1997; 120(Pt. 8):1279-1300.
  • 32] Graus F, Keime-Guibert F, Rene R, Benyahia B, Ribalta T, Ascaso C, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: Analysis of 200 patients. Brain 2001; 124 (Pt. 6):1138-1148.
  • 33] Shavit YB, Graus F, Probst A, Rene R, Steck AJ. Epilepsia partialis continua: A new manifestation of anti-Hu-associated paraneoplastic encephalomyelitis. Ann Neurol 1999; 45(2):255-258.
  • 34] Jacobs DA, Fung KM, Cook NM, Schalepfer WW, Goldberg HI, Stecker MM. Complex partial status epilepticus associated with anti-Hu paraneoplastic syndrome. J Neurol Sci 2003; 213(1-2):77-82.
  • 35] Tremont-Lukats IW, Fuller GN, Ribalta T, Giglio P, Groves MD. Paraneoplastic chorea: Case study with autopsy confirmation. Neuro-oncology 2002; 4(3):192-195.
  • 36] Sillevis Smitt P, Grefkens J, de Leeuw B, van den Bent M, van Putten W, Hooijkaas H, et al. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalo-myelitis/sensory neuronopathy. J Neurol 2002; 249(6):745-753.
  • 37] Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology 1998; 50(3):652-657.
  • 38] Bechich S, Graus F, Arboix A, Isidro A, Marti M, Rosell F. Anti-Hu-associated paraneoplastic sensory neuropathy and breast cancer. J Neurol 2000; 247(7):552-553.
  • 39] Greenlee JE, Steffens JD, Clawson SA, Hill K, Dalmau J. Anti-Hu antibodies in Merkel cell carcinoma. Ann Neurol 2002; 52(1):111-115.
  • 40] Ichimura M, Yamamoto M, Kobayashi Y, Kawakami O, Niimi Y, Hattori N, et al. Tissue distribution of pathological lesions and Hu antigen expression in paraneoplastic sensory neuronopathy. Acta Neuropathol (Berl) 1998; 95(6):641-648.
  • 41] Bernal F, Graus F, Pifarre A, Saiz A, Benyahia B, Ribalta T. Immunohistochemical analysis of anti-Hu-associated paraneoplastic encephalomyelitis. Acta Neuropathol (Berl) 2002; 103(5):509-515.
  • 42] Scaravilli F, An SF, Groves M, Thom M. The neuropathology of paraneoplastic syndromes. Brain Pathol 1999; 9(2):251-260.
  • 43] Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic limbic encephalitis: Neurological symptoms, immunological findings and tumour association in 50 patients. Brain 2000; 123(Pt. 7):1481-1494.
  • 44] Lawn ND, Westmoreland BF, Kiely MJ, Lennon VA, Vernino S. Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis. Mayo Clin Proc 2003; 78(11):1363-1368.
  • 45] Dalmau J, Graus F, Villarejo A, Posner JB, Blumenthal D, Thiessen B, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004; 127(Pt. 8):1831-1844.
  • 46] Voltz R, Gultekin SH, Rosenfeld MR, Gerstner E, Eichen J, Posner JB, et al. A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med 1999; 340(23):1788-1795.
  • 47] Antoine JC, Honnorat J, Anterion CT, Aguera M, Absi L, Fournel P, et al. Limbic encephalitis and immunological perturbations in two patients with thymoma. J Neurol Neurosurg Psychiatry 1995; 58(6):706-710.
  • 48] Buckley C, Oger J, Clover L, Tuzun E, Carpenter K, Jackson M, et al. Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol 2001; 50(1): 73-78.
  • 49] Pozo-Rosich P, Clover L, Saiz A, Vincent A, Graus F. Voltage-gated potassium channel antibodies in limbic encephalitis. Ann Neurol 2003; 54(4):530-533.
  • 50] Vincent A, Buckley C, Schott JM, Baker I, Dewar BK, Detert N, et al. Potassium channel antibody-associated encephalopathy: A potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004; 127(Pt. 3):701-712.
  • 51] Thieben MJ, Lennon VA, Boeve BF, Aksamit AJ, Keegan M, Vernino S. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology 2004; 62(7):1177-1182.
  • 52] Honnorat J, Antoine JC, Derrington E, Aguera M, Belin MF. Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 1996; 61(3):270-278.
  • 53] Scheid R, Honnorat J, Delmont E, Urbach H, Biniek R. A new anti-neuronal antibody in a case of paraneoplastic limbic encephalitis associated with breast cancer. J Neurol Neurosurg Psychiatry 2004; 75(2):338-340.
  • 54] Sutton I. Paraneoplastic neurological syndromes. Curr Opin Neurol 2002; 15(6):685-690.
  • 55] Rojas-Marcos I, Rousseau A, Keime-Guibert F, Rene R, Cartalat-Carel S, Delattre JY, et al. Spectrum of paraneoplastic neurologic disorders in women with breast and gynecologic cancer. Medicine (Baltimore) 2003; 82(3):216-223.
  • 56] Kastrup O, Meyring S, Diener HC. Atypical paraneoplastic brainstem encephalitis associated with anti-ri-antibodies due to thymic carcinoma with possible clinical response to immunoglobulins. Eur Neurol 2001; 45(4):285-287.
  • 57] Barnett M, Prosser J, Sutton I, Halmagyi GM, Davies L, Harper C, et al. Paraneoplastic brain stem encephalitis in a woman with anti-Ma2 antibody. J Neurol Neurosurg Psychiatry 2001; 70(2):222-225.
  • 58] Bataller L, Dalmau J. Neuro-ophthalmology and paraneoplastic syndromes. Curr Opin Neurol 2004; 17(1):3-8.
  • 59] Rajabally YA, Naz S, Farrell D, Abbott RJ. Paraneoplastic brainstem encephalitis with tetraparesis in a patient with anti-Ri antibodies. J Neurol 2004; 251(12):1528-1529.
  • 60] Nagashima T, Mizutani Y, Kawahara H, Maguchi S, Terayama Y, Shinohara T, et al. Anti-Hu paraneoplastic syndrome presenting with brainstem-cerebellar symptoms and Lambert-Eaton myasthenic syndrome. Neuropathology 2003; 23(3):230-238.
  • 61] Overeem S, Dalmau J, Bataller L, Nishino S, Mignot E, Verschuuren J, et al. Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis. Neurology 2004; 62(1): 138-140.
  • 62] Bataller L, Graus F, Saiz A, Vilchez JJ. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain 2001; 124(Pt. 2):437-443.
  • 63] Samii A, Dahlen DD, Spence AM, Maronian NC, Kraus EE, Lennon VA. Paraneoplastic movement disorder in a patient with non-Hodgkin's lymphoma and CRMP-5 autoantibody. Mov Disord 2003; 18(12):1556-1558.
  • 64] Kujawa KA, Niemi VR, Tomasi MA, Mayer NW, Cochran E, Goetz CG. Ballistic-choreic movements as the presenting feature of renal cancer. Arch Neurol 2001; 58(7): 1133-1135.
  • 65] Vernino S, Tuite P, Adler CH, Meschia JF, Boeve BF, Boasberg P, et al. Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma. Ann Neurol 2002; 51(5):625-630.
  • 66] Kinirons P, Fulton A, Keoghan M, Brennan P, Farrell MA, Moroney JT. Paraneoplastic limbic encephalitis (PLE) and chorea associated with CRMP-5 neuronal antibody. Neurology 2003; 61(11):1623-1624.
  • 67] Croteau D, Owainati A, Dalmau J, Rogers LR. Response to cancer therapy in a patient with a paraneoplastic choreiform disorder. Neurology 2001; 57(4):719-722.
  • 68] Shams'ili S, Grefkens J, de Leeuw B, van den Bent M, Hooijkaas H, van der Holt B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: Analysis of 50 patients. Brain 2003; 126(Pt. 6):1409-1418.
  • 69] Graus F, Lang B, Pozo-Rosich P, Saiz A, Casamitjana R, Vincent A. P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology 2002; 59(5):764-766.
  • 70] Bemal F, Shams'ili S, Rojas I, Sanchez-Valle R, Saiz A, Dalmau J, et al. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Neurology 2003; 60(2):230-234.
  • 71] Graus F, Dalmau J, Valldeoriola F, Ferrer I, Rene R, Marin C, et al. Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin's disease. J Neuroimmunol 1997; 74(1-2):55-61.
  • 72] Giometto B, Marchiori GC, Nicolao P, Scaravilli T, Lion A, Bardin PG, et al. Sub-acute cerebellar degeneration with anti-Yo autoantibodies: Immunohistochemical analysis of the immune reaction in the central nervous system. Neuropathol Appl Neurobiol 1997; 23(6):468-474.
  • 73] Rojas I, Graus F, Keime-Guibert F, Rene R, Delattre JY, Ramon JM, et al. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 2000; 55(5):713-715.
  • 74] Rudnick E, Khakoo Y, Antunes NL, Seeger RC, Brodeur GM, Shimada H, et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: Clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study. Med Pediatr Oncol 2001; 36(6):612-622.
  • 75] Gambini C, Conte M, Bernini G, Angelini P, Pession A, Paolucci P, et al. Neuroblastic tumors associated with opsoclonus-myoclonus syndrome: Histological, immunohisto-chemical and molecular features of 15 Italian cases. Virchows Arch 2003; 442(6):555-562.
  • 76] Berger JR, Mehari E. Paraneoplastic opsoclonus-myoclonus secondary to malignant melanoma. J Neurooncol 1999; 41(1):43-45.
  • 77] Bataller L, Rosenfeld MR, Graus F, Vilchez JJ, Cheung NK, Dalmau J. Autoantigen diversity in the opsoclonus-myoclonus syndrome. Ann Neurol 2003; 53(3):347-353.
  • 78] Pranzatelli MR, Travelstead AL, Tate ED, Allison TJ, Moticka EJ, Franz DN, et al. B- and T-cell markers in opsoclonus-myoclonus syndrome: Immunophenotyping of CSF lymphocytes. Neurology 2004; 62(9):1526-1532.
  • 79] Pranzatelli MR, Travelstead AL, Tate ED, Allison TJ, Verhulst SJ. CSF B-cell expansion in opsoclonus-myoclonus syndrome: A biomarker of disease activity. Mov Disord 2004; 19(7):770-777.
  • 80] Hormigo A, Dalmau J, Rosenblum MK, River ME, Posner JB. Immunological and pathological study of anti-Ri-associated encephalopathy. Ann Neurol 1994; 36(6): 896-902.
  • 81] Savchenko MS, Bazhin AV, Shifrina ON, Demoura SA, Kogan EA, Chuchalin AG, et al. Antirecoverin autoantibodies in the patient with non-small cell lung cancer but without cancer-associated retinopathy. Lung Cancer 2003; 41(3):363-367.
  • 82] Chan JW. Paraneoplastic retinopathies and optic neuropathies. Surv Ophthalmol 2003; 48(1):12-38.
  • 83] Amato AA, Collins MP. Neuropathies associated with malignancy. Semin Neurol 1998; 18(1):125-144.
  • 84] Keltner JL, Thirkill CE, Yip PT. Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: Eleven new cases and a review of 51 previously published cases. J Neuroophthalmol 2001; 21(3):173-187.
  • 85] Cross SA, Salomao DR, Parisi JE, Kryzer TJ, Bradley EA, Mines JA, et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol 2003; 54(1): 38-50.
  • 86] Gordon PH, Rowland LP, Younger DS, Sherman WH, Hays AP, Louis ED, et al. Lymphoproliferative disorders and motor neuron disease: An update. Neurology 1997; 48(6):1671-1678.
  • 87] Younger DS, Rowland LP, Latov N, Sherman W, Pesce M, Lange DJ, et al. Motor neuron disease and amyotrophic lateral sclerosis: Relation of high CSF protein content to paraproteinemia and clinical syndromes. Neurology 1990; 40(4):595-599.
  • 88] Schold SC, Cho ES, Somasundaram M, Posner JB. Subacute motor neuronopathy: A remote effect of lymphoma. Ann Neurol 1979; 5(3):271-287.
  • 89] Forsyth PA, Dalmau J, Graus F, Cwik V, Rosenblum MK, Posner JB. Motor neuron syndromes in cancer patients. Ann Neurol 1997; 41(6):722-730.
  • 90] Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) 1992; 71(2):59-72.
  • 91] Verma A, Berger JR, Snodgrass S, Petito C. Motor neuron disease: A paraneoplastic process associated with anti-hu antibody and small-cell lung carcinoma. Ann Neurol 1996; 40(1):112-116.
  • 92] Brown P, Marsden CD. The stiff man and stiff man plus syndromes. J Neurol 1999; 246(8): 648-652.
  • 93] Yoon JW, Jun HS. Cellular and molecular pathogenic mechanisms of insulin-dependent diabetes mellitus. Ann NY Acad Sci 2001; 928:200-211.
  • 94] Wessig C, Klein R, Schneider MF, Toyka KV, Naumann M, Sommer C. Neuropathology and binding studies in anti-amphiphysin-associated stiff-person syndrome. Neurology 2003; 61(2):195-198.
  • 95] De Camilli P, Thomas A, Cofiell R, Folli F, Lichte B, Piccolo G, et al. The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of Stiff-Man syndrome with breast cancer. J Exp Med 1993; 178(6):2219-2223.
  • 96] Floyd S, Butler MH, Cremona O, David C, Freyberg Z, Zhang X, et al. Expression of amphiphysin I, an autoantigen of paraneoplastic neurological syndromes, in breast cancer. Mol Med 1998; 4(1):29-39.
  • 97] Rudnicki SA, Dalmau J. Paraneoplastic syndromes of the spinal cord, nerve, and muscle. Muscle Nerve 2000; 23(12):1800-1818.
  • 98] Camdessanche JP, Antoine JC, Honnorat J, Vial C, Petiot P, Convers P, et al. Paraneo-plastic peripheral neuropathy associated with anti-Hu antibodies. A clinical and electro-physiological study of 20 patients. Brain 2002; 125(Pt. 1):166-175.
  • 99] Oh SJ, Gurtekin Y, Dropcho EJ, King P, Claussen GC. Anti-Hu antibody neuropathy: A clinical, electrophysiological, and pathological study. Clin Neurophysiol 2005; 116(1): 28-34.
  • 100] Antoine JC, Mosnier JF, Absi L, Convers P, Honnorat J, Michel D. Carcinoma associated paraneoplastic peripheral neuropathies in patients with and without anti-onconeural antibodies. J Neurol Neurosurg Psychiatry 1999; 67(1):7-14.
  • 101] Molinuevo JL, Graus F, Serrano C, Rene R, Guerrero A, Illa I. Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy. Ann Neurol 1998; 44(6):976-980.
  • 102] Antoine JC, Mosnier JF, Honnorat J, Convers P, Absi L, Lapras J, et al. Paraneoplastic demyelinating neuropathy, subacute sensory neuropathy, and anti-Hu antibodies: Clinicopathological study of an autopsy case. Muscle Nerve 1998; 21(7):850-857.
  • 103] Elrington GM, Murray NM, Spiro SG, Newsom-Davis J. Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients. J Neurol Neurosurg Psychiatry 1991; 54(9):764-767.
  • 104] Lee HR, Lennon VA, Camilleri M, Prather CM. Paraneoplastic gastrointestinal motor dysfunction: Clinical and laboratory characteristics. Am J Gastroenterol 2001; 96(2): 373-379.

110 111 112

115 116]

120] 121

De Giorgio R, Guerrini S, Barbara G, Stanghellini V, De Ponti F, Corinaldesi R, et al. Inflammatory neuropathies of the enteric nervous system. Gastroenterology 2004; 126(7): 1872-1883.

De Giorgio R, Bovara M, Barbara G, Canossa M, Sarnelli G, De Ponti F, et al. Anti-HuD-induced neuronal apoptosis underlying paraneoplastic gut dysmotility. Gastroenterology 2003; 125(1):70-79.

Wanschitz J, Hainfellner JA, Kristoferitsch W, Drlicek M, Budka H. Ganglionitis in paraneoplastic subacute sensory neuronopathy: A morphologic study. Neurology 1997; 49(4):1156-1159.

Vernino S, Low PA, Fealey RD, Stewart JD, Farrugia G, Lennon VA. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med 2000; 343(12):847-855.

O'Suilleabhain P, Low PA, Lennon VA. Autonomic dysfunction in the Lambert-Eaton myasthenic syndrome: Serologic and clinical correlates. Neurology 1998; 50(1):88-93. Croft PB, Urich H, Wilkinson M. Peripheral neuropathy of sensorimotor type associated with malignant disease. Brain 1967; 90(1):31-66.

Croft PB, Wilkinson M. The course and prognosis in some types of carcinomatous neuromyopathy. Brain 1969; 92(1):1-8.

Corbo M, Balmaceda C. Peripheral neuropathy in cancer patients. Cancer Invest 2001; 19(4):369-382.

Antoine JC, Honnorat J, Camdessanche JP, Magistris M, Absi L, Mosnier JF, et al. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol 2001; 49(2):214-221. Sutton I, Winer JB. The immunopathogenesis of paraneoplastic neurological syndromes. Clin Sci (Lond) 2002; 102(5):475-486.

Storstein A, Vedeler C. Neuropathy and malignancy: A retrospective survey. J Neurol 2001; 248(4):322-327.

Peterson K, Forsyth PA, Posner JB. Paraneoplastic sensorimotor neuropathy associated with breast cancer. J Neurooncol 1994; 21(2):159-170.

Kloos L, Sillevis Smitt P, Ang CW, Kruit W, Stoter G. Paraneoplastic ophthalmoplegia and subacute motor axonal neuropathy associated with anti-GQ1b antibodies in a patient with malignant melanoma. J Neurol Neurosurg Psychiatry 2003; 74(4):507-509. De Toni L, Marconi S, Nardelli E, Alberti D, Borsellino G, Fracasso G, et al. Gangliosides act as onconeural antigens in paraneoplastic neuropathies. J Neuroimmunol 2004; 156(1-2): 178-187.

Antoine JC, Camdessanche JP, Ferraud K, Caudie C. Antiganglioside antibodies in paraneoplastic peripheral neuropathies. J Neurol Neurosurg Psychiatry 2004; 75(12): 1765-1767.

Kelly JJ, Karcher DS. Lymphoma and peripheral neuropathy: A clinical review. Muscle Nerve 2005; 31(3):301-313.

Lisak RP, Mitchell M, Zweiman B, Orrechio E, Asbury AK. Guillain-Barre syndrome and Hodgkin's disease: Three cases with immunological studies. Ann Neurol 1977; 1(1):72-78. Vigliani MC, Magistrello M, Polo P, Mutani R, Chio A. Risk of cancer in patients with Guillain-Barre syndrome (GBS). A population-based study. J Neurol 2004; 251(3): 321-326.

Antoine JC, Mosnier JF, Lapras J, Convers P, Absi L, Laurent B, et al. Chronic inflammatory demyelinating polyneuropathy associated with carcinoma. J Neurol Neurosurg Psychiatry 1996; 60(2):188-190.

Mygland A, Monstad P. Chronic polyneuropathies in Vest-Agder, Norway. Eur J Neurol 2001; 8(2):157-165.

[125] Busby M, Donaghy M. Chronic dysimmune neuropathy. A subclassification based upon the clinical features of 102 patients. J Neurol 2003; 250(6):714-724.

126] Vital A. Paraproteinemic neuropathies. Brain Pathol 2001; 11(4):399-407.

127] Kelly JJ, Jr, Kyle RA, O'Brien PC, Dyck PJ. Prevalence of monoclonal protein in peripheral neuropathy. Neurology 1981; 31(11):1480-1483.

128] Nobile-Orazio E, Barbieri S, Baldini L, Marmiroli P, Carpo M, Premoselli S, et al. Peripheral neuropathy in monoclonal gammopathy of undetermined significance: Prevalence and immunopathogenetic studies. Acta Neurol Scand 1992; 85(6):383-390.

129] Latov N, Renaud S. Effector mechanisms in anti-MAG antibody-mediated and other demyelinating neuropathies. J Neurol Sci 2004; 220(1-2):127-129.

130] Steck AJ, Erne B, Gabriel JM, Schaeren-Wiemers N. Paraproteinaemic neuropathies. Brain Pathol 1999; 9(2):361-368.

131] Dispenzieri A, Kyle RA, Lacy MQ, Rajkumar SV, Therneau TM, Larson DR, et al. POEMS syndrome: Definitions and long-term outcome. Blood 2003; 101(7):2496-2506.

132] Dispenzieri A. POEMS syndrome. Hematology (Am Soc Hematol Educ Program) 2005: 360-367.

133] Vincent A, McConville J, Farrugia ME, Bowen J, Plested P, Tang T, et al. Antibodies in myasthenia gravis and related disorders. Ann NY Acad Sci 2003; 998:324-335.

134] Honnorat J, Cartalat-Carel S. Advances in paraneoplastic neurological syndromes. Curr Opin Oncol 2004; 16(6):614-620.

135] Wirtz PW, Willcox N, Roep BO, Lang B, Wintzen AR, Newsom-Davis J, et al. HLA-B8 in patients with the Lambert-Eaton myasthenic syndrome reduces likelihood of associated small cell lung carcinoma. Ann NY Acad Sci 2003; 998:200-201.

136] Wirtz PW, Willcox N, van der Slik AR, Lang B, Maddison P, Koeleman BP, et al. HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert-Eaton myasthenic syndrome. J Neuroimmunol 2005; 159(1-2):230-237.

137] Fukuda T, Motomura M, Nakao Y, Shiraishi H, Yoshimura T, Iwanaga K, et al. Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cere-bellar degeneration with Lambert-Eaton myasthenic syndrome. Ann Neurol 2003; 53(1): 21-28.

138] Viallard JF, Vincent A, Moreau JF, Parrens M, Pellegrin JL, Ellie E. Thymoma-associated neuromyotonia with antibodies against voltage-gated potassium channels presenting as chronic intestinal pseudo-obstruction. Eur Neurol 2005; 53(2):60-63.

139] Hart IK, Maddison P, Newsom-Davis J, Vincent A, Mills KR. Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain 2002; 125(Pt. 8):1887-1895.

140] O'Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 1988; 111(Pt. 3):577-596.

141] Vernino S, Lennon VA. Ion channel and striational antibodies define a continuum of autoimmune neuromuscular hyperexcitability. Muscle Nerve 2002; 26(5):702-707.

142] Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med 2003; 349(16):1543-1554.

143] Alamowitch S, Graus F, Uchuya M, Rene R, Bescansa E, Delattre JY. Limbic encephalitis and small cell lung cancer. Clinical and immunological features. Brain 1997; 120(Pt. 6): 923-928.

144] Storstein A, Monstad SE, Honnorat J, Vedeler CA. Paraneoplastic antibodies detected by isoelectric focusing of cerebrospinal fluid and serum. J Neuroimmunol 2004; 155(1-2): 150-154.

145] Blaes F, Jauss M, Kraus J, Oschmann P, Krasenbrink I, Kaps M, et al. Adult paraneo-plastic opsoclonus-myoclonus syndrome associated with antimitochondrial autoantibo-dies. J Neurol Neurosurg Psychiatry 2003; 74(11):1595-1596.

  • 146] Kumar A, Lajara-Nanson WA, Neilson RW, Jr. Paraneoplastic Opsoclonus-Myoclonus Syndrome: Initial presentation of non-Hodgkins lymphoma. J Neurooncol 2005; 73(1): 43-45.
  • 147] McLeod JG. Investigation of peripheral neuropathy. J Neurol Neurosurg Psychiatry 1995; 58(3):274-283.
  • 148] Younes-Mhenni S, Janier MF, Cinotti L, Antoine JC, Tronc F, Cottin V, et al. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain 2004; 127(Pt. 10):2331-2338.
  • 149] Linke R, Schroeder M, Helmberger T, Voltz R. Antibody-positive paraneoplastic neurologic syndromes: Value of CT and PET for tumor diagnosis. Neurology 2004; 63(2): 282-286.
  • 150] Antoine JC, Cinotti L, Tilikete C, Bouhour F, Camdessanche JP, Confavreux C, et al. [18F]fluorodeoxyglucose positron emission tomography in the diagnosis of cancer in patients with paraneoplastic neurological syndrome and anti-Hu antibodies. Ann Neurol 2000; 48(1):105-108.
  • 151] Rees JH, Hain SF, Johnson MR, Hughes RA, Costa DC, Ell PJ, et al. The role of [18F] fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders. Brain 2001; 124(Pt. 11):2223-2231.
  • 152] Frings M, Antoch G, Knorn P, Freudenberg L, Bier U, Timmann D, et al. Strategies in detection ofthe primary tumour in anti-Yo associated paraneoplastic cerebellar degeneration. J Neurol 2005; 252(2):197-201.
  • 153] Peterson K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 1992; 42(10):1931-1937.
  • 154] Darnell RB. Onconeural antigens and the paraneoplastic neurologic disorders: At the intersection of cancer, immunity, and the brain. Proc Natl Acad Sci USA 1996; 93(10): 4529-4536.
  • 155] Moll JW, Antoine JC, Brashear HR, Delattre J, Drlicek M, Dropcho EJ, et al. Guidelines on the detection of paraneoplastic anti-neuronal-specific antibodies: Report from the Workshop to the Fourth Meeting of the International Society of Neuro-Immunology on paraneoplastic neurological disease, held October 22-23, 1994, in Rotterdam, The Netherlands. Neurology 1995; 45(10):1937-1941.
  • 156] Antoine JC, Absi L, Honnorat J, Boulesteix JM, de Brouker T, Vial C, et al. Antiamphi-physin antibodies are associated with various paraneoplastic neurological syndromes and tumors. Arch Neurol 1999; 56(2):172-177.
  • 157] Moll JW, Antoine JC, Brashear HR, Delattre J, Drlicek M, Dropcho EJ, et al. Guidelines on the detection of paraneoplastic anti-neuronal-specific antibodies: Report from the Workshop to the Fourth Meeting of the International Society of Neuro-Immunology on paraneoplastic neurological disease, held October 22-23, 1994, in Rotterdam, The Netherlands. Neurology 1995; 45(10):1937-1941.
  • 158] Sillevis-Smitt P, Manley G, Moll JW, Dalmau J, Posner JB. Pitfalls in the diagnosis of autoantibodies associated with paraneoplastic neurologic disease. Neurology 1996; 46(6): 1739-1741.
  • 159] Furneaux HF, Reich L, Posner JB. Autoantibody synthesis in the central nervous system of patients with paraneoplastic syndromes. Neurology 1990; 40(7):1085-1091.
  • 160] Vega F, Graus F, Chen QM, Poisson M, Schuller E, Delattre JY. Intrathecal synthesis of the anti-Hu antibody in patients with paraneoplastic encephalomyelitis or sensory neuro-nopathy: Clinical-immunologic correlation. Neurology 1994; 44(11):2145-2147.
  • 161] Willison HJ, Ang W, Gilhus NE, Graus F, Liblau R, Vedeler C, et al. EFNS task force report: A questionnaire-based survey on the service provision and quality assurance for determination of diagnostic autoantibody tests in European neuroimmunology centres. European Federation of Neurological Societies. Eur J Neurol 2000; 7(6): 625-628.
  • 162] Adamus G, Ren G, Weleber RG. Autoantibodies against retinal proteins in paraneoplastic and autoimmune retinopathy. BMC Ophthalmol 2004; 4-5:1-9.
  • 163] Rauer S, Kaiser R. Enzyme linked immunosorbent assay using recombinant HuD-auto-antigen for serodiagnosis of paraneoplastic neurological syndromes. Acta Neurol Scand 2001; 103(4):248-254.
  • 164] Verschuuren JJ, Perquin M, ten Velde G, De Baets M, Vriesman PB, Twijnstra A. Anti-Hu antibody titre and brain metastases before and after treatment for small cell lung cancer. J Neurol Neurosurg Psychiatry 1999; 67(3):353-357.
  • 165] Storstein A, Monstad SE, Nakkestad HL, Husebye ES, Vedeler CA. Paraneoplastic antibodies against HuD detected by a sensitive radiobinding assay. J Neurol 2004; 251(2):197-203.
  • 166] Knudsen A, Monstad SE, Dorum A, Lonning PE, Salvesen HB, Drivsholm L, et al. Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique. Cancer Immunol Immunother 2006; 55(10): 1280-1284.
  • 167] Monstad SE, Drivsholm L, Storstein A, Aarseth JH, Haugen M, Lang B, et al. Hu and voltage-gated calcium channel (VGCC) antibodies related to the prognosis of small-cell lung cancer. J Clin Oncol 2004; 22(5):795-800.
  • 168] Drlicek M, Bianchi G, Bogliun G, Casati B, Grisold W, Kolig C, et al. Antibodies of the anti-Yo and anti-Ri type in the absence of paraneoplastic neurological syndromes: A long-term survey of ovarian cancer patients. J Neurol 1997; 244(2):85-89.
  • 169] Graus F, Vincent A, Pozo-Rosich P, Sabater L, Saiz A, Lang B, et al. Anti-glial nuclear antibody: Marker of lung cancer-related paraneoplastic neurological syndromes. J Neuroimmunol 2005; 165(1-2):166-171.
  • 170] Dalmau J, Furneaux HM, Cordon-Cardo C, Posner JB. The expression of the Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues. Am J Pathol 1992; 141(4):881-886.
  • 171] Dalmau J, Graus F, Cheung NK, Rosenblum MK, Ho A, Canete A, et al. Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. Cancer 1995; 75(1):99-109.
  • 172] Gultekin SH, Dalmau J, Graus Y, Posner JB, Rosenblum MK. Anti-Hu immunolabeling as an index of neuronal differentiation in human brain tumors: A study of 112 central neuroepithelial neoplasms. Am J Surg Pathol 1998; 22(2):195-200.
  • 173] Darnell JC, Albert ML, Darnell RB. Cdr2, a target antigen of naturally occuring human tumor immunity, is widely expressed in gynecological tumors. Cancer Res 2000; 60(8): 2136-2139.
  • 174] Dalmau J, Furneaux HM, Gralla RJ, Kris MG, Posner JB. Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer—a quantitative western blot analysis. Ann Neurol 1990; 27(5):544-552.
  • 175] Pawelec G, Heinzel S, Kiessling R, Muller L, Ouyang Q, Zeuthen J. Escape mechanisms in tumor immunity: A year 2000 update. Crit Rev Oncog 2000; 11(2):97-133.
  • 176] Furneaux HM, Rosenblum MK, Dalmau J, Wong E, Woodruff P, Graus F, et al. Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration. N Engl J Med 1990; 322(26):1844-1851.

180 181

Sutton IJ, Fursdon Davis CJ, Esiri MM, Hughes S, Amyes ER, Vincent A. Anti-Yo antibodies and cerebellar degeneration in a man with adenocarcinoma of the esophagus. Ann Neurol 2001; 49(2):253-257.

Verschuuren J, Chuang L, Rosenblum MK, Lieberman F, Pryor A, Posner JB, et al. Inflammatory infiltrates and complete absence of Purkinje cells in anti-Yo-associated paraneoplastic cerebellar degeneration. Acta Neuropathol (Berl) 1996; 91(5):519-525. Carpentier AF, Voltz R, DesChamps T, Posner JB, Dalmau J, Rosenfeld MR. Absence of HuD gene mutations in paraneoplastic small cell lung cancer tissue. Neurology 1998; 50(6):1919.

Lang B, Vincent A. Autoantibodies to ion channels at the neuromuscular junction. Autoimmun Rev 2003; 2(2):94-100.

Adamus G. Autoantibody-induced apoptosis as a possible mechanism of autoimmune retinopathy. Autoimmun Rev 2003; 2(2):63-68.

Sillevis Smitt P, Kinoshita A, De Leeuw B, Moll W, Coesmans M, Jaarsma D, et al. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med 2000; 342(1):21-27.

Lang B, Dale RC, Vincent A. New autoantibody mediated disorders of the central nervous system. Curr Opin Neurol 2003; 16(3):351-357.

Arbuckle MR, James JA, Kohlhase KF, Rubertone MV, Dennis GJ, Harley JB. Development of anti-dsDNA autoantibodies prior to clinical diagnosis of systemic lupus erythe-matosus. Scand J Immunol 2001; 54(1-2):211-219.

Greenlee JE, Parks TN, Jaeckle KA. Type IIa ('anti-Hu') antineuronal antibodies produce destruction of rat cerebellar granule neurons in vitro. Neurology 1993; 43(10): 2049-2054.

Greenlee JE, Burns JB, Rose JW, Jaeckle KA, Clawson S. Uptake of systemically administered human anticerebellar antibody by rat Purkinje cells following blood-brain barrier disruption. Acta Neuropathol (Berl) 1995; 89(4):341-345.

Stich O, Graus F, Rasiah C, Rauer S. Qualitative evidence of anti-Yo-specific intrathecal antibody synthesis in patients with paraneoplastic cerebellar degeneration. J Neuroimmu-nol 2003; 141(1-2):165-169.

Brashear HR, Caccamo DV, Heck A, Keeney PM. Localization of antibody in the central nervous system of a patient with paraneoplastic encephalomyeloneuritis. Neurology 1991; 41(10):1583-1587.

Dalmau J, Furneaux HM, Rosenblum MK, Graus F, Posner JB. Detection of the anti-Hu antibody in specific regions of the nervous system and tumor from patients with paraneoplastic encephalomyelitis/sensory neuronopathy. Neurology 1991; 41(11): 1757-1764.

Sommer C, Weishaupt A, Brinkhoff J, Biko L, Wessig C, Gold R, et al. Paraneoplastic stiff-person syndrome: Passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet 2005; 365(9468):1406-1411.

Schafer KH, Klotz M, Mergner D, Mestres P, Schimrigk K, Blaes F. IgG-mediated cytotoxicity to myenteric plexus cultures in patients with paraneoplastic neurological syndromes. J Autoimmun 2000; 15(4):479-484.

Tanaka K, Ding X, Tanaka M. Effects of antineuronal antibodies from patients with paraneoplastic neurological syndrome on primary-cultured neurons. J Neurol Sci 2004; 217(1):25-30.

Okano HJ, Park WY, Corradi JP, Darnell RB. The cytoplasmic Purkinje onconeural antigen cdr2 down-regulates c-Myc function: Implications for neuronal and tumor cell survival. Genes Dev 1999; 13(16):2087-2097.

  • 194] Tanaka K, Tanaka M, Igarashi S, Onodera O, Miyatake T, Tsuji S. Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody. 2. Passive transfer of murine mononuclear cells activated with recombinant Yo protein to paraneo-plastic cerebellar degeneration lymphocytes in severe combined immunodeficiency mice. Clin Neurol Neurosurg 1995; 97(1):101-105.
  • 195] Graus F, Illa I, Agusti M, Ribalta T, Cruz-Sanchez F, Juarez C. Effect of intraventricular injection of an anti-Purkinje cell antibody (anti-Yo) in a guinea pig model. J Neurol Sci 1991; 106(1):82-87.
  • 196] Sillevis Smitt PA, Manley GT, Posner JB. Immunization with the paraneoplastic encepha-lomyelitis antigen HuD does not cause neurologic disease in mice. Neurology 1995; 45(10): 1873-1878.
  • 197] Tanaka M, Tanaka K, Onodera O, Tsuji S. Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody. 1. Mouse strains bearing different MHC molecules produce antibodies on immunization with recombinant Yo protein, but do not cause Purkinje cell loss. Clin Neurol Neurosurg 1995; 97(1): 95-100.
  • 198] Dalmau J, Gultekin HS, Posner JB. Paraneoplastic neurologic syndromes: Pathogenesis and physiopathology. Brain Pathol 1999; 9(2):275-284.
  • 199] Verschuuren JJ, Dalmau J, Hoard R, Posner JB. Paraneoplastic anti-Hu serum: Studies on human tumor cell lines. J Neuroimmunol 1997; 79(2):202-210.
  • 200] Carpentier AF, Rosenfeld MR, Delattre JY, Whalen RG, Posner JB, Dalmau J. DNA vaccination with HuD inhibits growth of a neuroblastoma in mice. Clin Cancer Res 1998; 4(11):2819-2824.
  • 201] Newsom-Davis J. Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome. Semin Neurol 2003; 23(2):191-198.
  • 202] Storstein A, Knudsen A, Bjorge L, Meri S, Vedeler C. Heterogeneous expression of CD59 on human Purkinje cells. Neurosci Lett 2004; 362(1):21-25.
  • 203] Panegyres PK, Reading MC, Esiri MM. The inflammatory reaction of paraneoplastic ganglionitis and encephalitis: An immunohistochemical study. J Neurol 1993; 240(2): 93-97.
  • 204] Jean WC, Dalmau J, Ho A, Posner JB. Analysis of the IgG subclass distribution and inflammatory infiltrates in patients with anti-Hu-associated paraneoplastic encephalomy-elitis. Neurology 1994; 44(1):140-147.
  • 205] Hainfellner JA, Kristoferitsch W, Lassmann H, Bernheimer H, Neisser A, Drlicek M, et al. T-cell-mediated ganglionitis associated with acute sensory neuronopathy. Ann Neurol 1996; 39(4):543-547.
  • 206] Albert ML, Austin LM, Darnell RB. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol 2000; 47(1):9-17.
  • 207] Tanaka M, Tanaka K, Tokiguchi S, Shinozawa K, Tsuji S. Cytotoxic T cells against a peptide of Yo protein in patients with paraneoplastic cerebellar degeneration and anti-Yo antibody. J Neurol Sci 1999; 168(1):28-31.
  • 208] Albert ML, Darnell JC, Bender A, Francisco LM, BhardwajN, Darnell RB. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med 1998; 4(11): 1321-1324.
  • 209] Tanaka M, Maruyama Y, Sugie M, Motizuki H, Kamakura K, Tanaka K. Cytotoxic T cell activity against peptides of Hu protein in anti-Hu syndrome. J Neurol Sci 2002; 201(1-2):9-12.
  • 210] Voltz R, Dalmau J, Posner JB, Rosenfeld MR. T-cell receptor analysis in anti-Hu associated paraneoplastic encephalomyelitis. Neurology 1998; 51(4):1146-1150.
  • 211] Pellkofer H, Schubart AS, Hoftberger R, Schutze N, Pagany M, Schuller M, et al. Modelling paraneoplastic CNS disease: T-cells specific for the onconeuronal antigen PNMA1 mediate autoimmune encephalomyelitis in the rat. Brain 2004; 127(Pt. 8): 1822-1830.
  • 212] Corriveau RA, Huh GS, Shatz CJ. Regulation of class I MHC gene expression in the developing and mature CNS by neural activity. Neuron 1998; 21(3):505-520.
  • 213 [214
  • 215 [216 [217 [218
  • 219 [220 [221

[222

[223

[224

[225

Darnell RB. Immunologic complexity in neurons. Neuron 1998; 21:947-950. Christinck ER, Luscher MA, Barber BH, Williams DB. Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis. Nature 1991; 352(6330):67-70.

Huseby ES, Liggitt D, Brabb T, Schnabel B, Ohlen C, Goverman J. A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. J Exp Med 2001; 194(5): 669-676.

Benyahia B, Liblau R, Merle-Beral H, Tourani JM, Dalmau J, Delattre JY. Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. Ann Neurol 1999; 45(2):162-167.

Plonquet A, Gherardi RK, Creange A, Antoine JC, Benyahia B, Grisold W, et al. Oligo-clonal T-cells in blood and target tissues of patients with anti-Hu syndrome. J Neuroimmunol 2002; 122(1-2):100-105.

Sutton IJ, Steele J, Savage CO, Winer JB, Young LS. An interferon-gamma ELISPOT and immunohistochemical investigation of cytotoxic T lymphocyte-mediated tumour immunity in patients with paraneoplastic cerebellar degeneration and anti-Yo antibodies. J Neuroimmunol 2004; 150(1-2):98-106.

Grisold W, Drlicek M, Liszka-Setinek U, Wondrusch E. Anti-tumour therapy in paraneoplastic neurological disease. Clin Neurol Neurosurg 1995; 97(1):106-111. Graus F, Delattre JY. Immune modulation of paraneoplastic neurologic disorders. Clin Neurol Neurosurg 1995; 97(1):112-116.

Candler PM, Hart PE, Barnett M, Weil R, Rees JH. A follow up study of patients with paraneoplastic neurological disease in the United Kingdom. J Neurol Neurosurg Psychiatry 2004; 75(10):1411-1415.

Peltola J, Hietaharju A, Rantala I, Lehtinen T, Haapasalo H. A reversible neuronal antibody (anti-Tr) associated paraneoplastic cerebellar degeneration in Hodgkin's disease. Acta Neurol Scand 1998; 98(5):360-363.

Russo C, Cohn SL, Petruzzi MJ, de Alarcon PA. Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: A report from the Pediatric Oncology Group. Med Pediatr Oncol 1997; 28(4):284-288. Cher LM, Hochberg FH, Teruya J, Nitschke M, Valenzuela RF, Schmahmann JD, et al. Therapy for paraneoplastic neurologic syndromes in six patients with protein A column immunoadsorption. Cancer 1995; 75(7):1678-1683.

Blaes F, Strittmatter M, Merkelbach S, Jost V, Klotz M, Schimrigk K, et al. Intravenous immunoglobulins in the therapy of paraneoplastic neurological disorders. J Neurol 1999; 246(4):299-303.

Vernino S, O'Neill BP, Marks RS, O'Fallon JR, Kimmel DW. Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro-oncology 2004; 6(1):55-62. Shams'ili S, deBeukelaar J, Gratama JW, Hooijkaas H, van den Bent M, Van't Veer M, et al. An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol 2006; 253(1):16-20.

Uchuya M, Graus F, Vega F, Rene R, Delattre JY. Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. J Neurol Neurosurg Psychiatry 1996; 60(4):388-392.

  • 229] Arbusow V, Voltz RD, Strupp M, Schulz P. Successful treatment of peripheral paraneo-plastic neurological syndromes in small cell cancer. J Neurol Neurosurg Psychiatry 1998; 65(4):609-610.
  • 230] Keime-Guibert F, Graus F, Fleury A, Rene R, Honnorat J, Broet P, et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 2000; 68(4):479-482.
  • 231] Sanders DB. Lambert-eaton myasthenic syndrome: Diagnosis and treatment. Ann NY Acad Sci 2003; 998:500-508.
  • 232] Graus F, Bonaventura I, Uchuya M, Valls-Sole J, Rene R, Leger JM, et al. Indolent anti-Hu-associated paraneoplastic sensory neuropathy. Neurology 1994; 44(12):2258-2261.
  • 233] Byrne T, Mason WP, Posner JB, Dalmau J. Spontaneous neurological improvement in anti-Hu associated encephalomyelitis. J Neurol Neurosurg Psychiatry 1997; 62(3): 276-278.

This page intentionally left blank

ADVANCES IN CLINICAL CHEMISTRY, VOL. 44

A Disquistion On The Evils Of Using Tobacco

A Disquistion On The Evils Of Using Tobacco

Among the evils which a vitiated appetite has fastened upon mankind, those that arise from the use of Tobacco hold a prominent place, and call loudly for reform. We pity the poor Chinese, who stupifies body and mind with opium, and the wretched Hindoo, who is under a similar slavery to his favorite plant, the Betel but we present the humiliating spectacle of an enlightened and christian nation, wasting annually more than twenty-five millions of dollars, and destroying the health and the lives of thousands, by a practice not at all less degrading than that of the Chinese or Hindoo.

Get My Free Ebook


Post a comment